1. Home
  2. CTM vs IMUX Comparison

CTM vs IMUX Comparison

Compare CTM & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CTM

Castellum Inc.

HOLD

Current Price

$1.06

Market Cap

93.0M

Sector

Technology

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$0.62

Market Cap

85.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTM
IMUX
Founded
2019
2016
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.0M
85.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CTM
IMUX
Price
$1.06
$0.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$3.00
$6.00
AVG Volume (30 Days)
1.7M
1.2M
Earning Date
11-07-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,606,863.00
N/A
Revenue This Year
$23.00
N/A
Revenue Next Year
$11.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.09
N/A
52 Week Low
$0.26
$0.56
52 Week High
$2.83
$1.39

Technical Indicators

Market Signals
Indicator
CTM
IMUX
Relative Strength Index (RSI) 46.24 36.87
Support Level $1.00 $0.66
Resistance Level $1.17 $0.70
Average True Range (ATR) 0.06 0.04
MACD 0.01 -0.00
Stochastic Oscillator 22.92 25.81

Price Performance

Historical Comparison
CTM
IMUX

About CTM Castellum Inc.

Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: